Loading...
  • vitro
  • Related HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: observations of a single Chinese center. (nih.gov)
  • Thrombopoietin also has stimulatory effects on more primitive multilineage progenitors and stem cells in vitro and in animal models. (clinicaltrials.gov)
  • TPO was later shown to stimulate proliferation of more primitive bone marrow stem and progenitor cells in vitro and in animal models, suggesting it could have an impact of production of red and white blood cells as well as platelets. (aamds.org)
  • Cyclophosphamide
  • Cyclophosphamide is designed to interfere with the multiplication of cancer cells, which may slow or stop their growth and spread throughout the body. (knowcancer.com)
  • malignant cells
  • Indeed, the anti-tumor effect of these cytoablative strategies is believed to be caused not only by direct effects on the malignant cells, but also in part by induction of new T cell responses, as T cells expand within the lymphopenic environment ( 9 ). (jimmunol.org)
  • While many of these therapies have offered substantial benefit for eradication of primary tumors, the incidence of disease relapse is still a commonly encountered problem that results from residual malignant cells and/or tumor metastases [ 3 , 4 ]. (jcancer.org)
  • After binding to CD52 + cells, an antibody-dependent lysis of malignant cells occurs. (drugs.com)
  • cancer immunotherapy
  • Most recently, cancer immunotherapy field is growing tremendously, such as utilization of cancer vaccinations, chimeric antigen receptor (CAR) T-cell therapy and immune checkpoint blockade therapy [ 10 , 11 ]. (jcancer.org)
  • therapeutic
  • A variety of therapeutic options are now available for advanced renal cell cancer, including antiangiogenic and anti-mTOR agents. (jcancer.org)
  • responses
  • Subjects with platelet, red cell, and/or neutrophil responses at 24 weeks may continue study medication (extended access) until they meet off study criteria. (aamds.org)
  • The innate immune cells can release signals which are essential to stimulate responses from both T cells and B cells [ 31 ]. (jcancer.org)
  • While minor histocompatibility antigens and possibly attached or presented peptide epitopes have been found as one class of target antigens for tumor-directed T-cell responses, natural killer (NK) cell responses are another antitumor effector mechanism postulated. (bloodjournal.org)
  • whereas
  • Humoral immunity can neutralize and eradicate outside microbes and toxins via antibodies produced by B cells [ 24 - 26 ], whereas cellular immunity responds more quickly to eradicate intracellular microbes through recognition of antigens, activation of antigen presenting cells (APCs), activation and proliferation of T cells. (jcancer.org)
  • malignancy
  • Renal cell carcinoma is an aggressive malignancy with a high propensity for both early and metachronous regional and distant metastasis. (springer.com)
  • bone marrow
  • Hematopoietic stem cell transplantation is the only curative choice for a number of inherited bone marrow failure syndromes, hemoglobinopathies, metabolic disorders and primary immune deficiencies. (clinicaltrials.gov)
  • Nine became transfusion-independent for platelets (median increase in platelet count 34,000/micro l), six had improved hemoglobin levels (median increase of 3.8g/dL), including three previously dependent on red cell transfusions achieving transfusion-independence, and eight exhibiting increased neutrophil counts (median increase 590 cells/mico L). Serial bone marrow biopsies demonstrated normalization of tri-lineage hematopoiesis in responders, without increased fibrosis . (aamds.org)
  • NY-ESO-1 gene and protein expression (inset: immunohistochemistry analysis of myeloma cells in bone marrow). (bloodjournal.org)
  • antigen
  • NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. (nih.gov)
  • Alemtuzumab binds to CD52, a nonmodulating antigen present on the surface of B and T lymphocytes, a majority of monocytes, macrophages, NK cells, and a subpopulation of granulocytes. (drugs.com)
  • Two candidate target antigens were identified: cancer/testis (CT) antigen NY-ESO-1 and BCMA, a plasma-cell membrane receptor. (bloodjournal.org)
  • This now is the first report of antibodies with tumor-lytic properties induced in vivo against a cell surface antigen. (bloodjournal.org)